- Home
- HTH vs ANIP Comparison
HTH vs ANIP Comparison
Compare HTH & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | ANIP |
|---|---|---|
| Founded | 1998 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2003 | 1999 |
Fundamental Metrics
Financial Performance| Metric | HTH | ANIP |
|---|---|---|
| Price | $37.43 | $79.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $37.50 | ★ $110.00 |
| AVG Volume (30 Days) | 241.2K | ★ 291.5K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | 51.72 | ★ 419.23 |
| EPS | 2.64 | ★ 3.32 |
| Revenue | $152,188,000.00 | ★ $206,547,000.00 |
| Revenue This Year | N/A | $21.01 |
| Revenue Next Year | $3.22 | $17.59 |
| P/E Ratio | ★ $14.19 | $24.12 |
| Revenue Growth | ★ 15.52 | 2.47 |
| 52 Week Low | $28.43 | $56.71 |
| 52 Week High | $40.41 | $99.50 |
Technical Indicators
Market Signals| Indicator | HTH | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 55.92 | 56.27 |
| Support Level | $36.67 | $77.54 |
| Resistance Level | $38.30 | $83.87 |
| Average True Range (ATR) | 0.68 | 2.78 |
| MACD | 0.11 | 0.33 |
| Stochastic Oscillator | 69.63 | 70.38 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.